§ The forum spotlights data analytics, AI-driven solutions, regulatory perspectives, and more
§ It addresses scalability, process control, and availability of transformative therapies
§ It reinforces the company’s role as a strong collaborator in biomanufacturing
Sartorius, a leading life science company, will host the Sartorius
Cell & Gene Therapy (CGT) Forum in Boston, Massachusetts on October 23. The
event will convene key opinion leaders and subject matter experts from across
the research and manufacturing landscape. The talks and presentations will
explore how cutting-edge technologies, regulatory insights, and investment
strategies are shaping the future of cell and gene therapies — and driving
scalability, process control, and cost-effective availability of these
transformative treatments.
The CGT Forum will highlight three key themes shaping the
future of the field:
§ The transformative role of data analytics: From
early-stage R&D to scalable manufacturing and patient access, experts will
showcase how data is setting new benchmarks for efficiency, quality, and impact
across the CGT value chain § Accelerating innovation in CGT: Attendees will learn
about breakthrough technologies and novel processes transforming the cell,
gene, and nucleic acids landscape § Shaping the next chapter of the CGT industry: Peers
and thought leaders will connect to explore emerging trends, technologies, and
approaches that will define the next generation of cell and gene therapies
Altogether, the forum aims to provide attendees with
insights for enhancing scalability and control, ultimately improving access to
cell and gene therapies. In addition, the forum will feature expert-led
sessions on regulatory perspectives, AI-driven analytics, and start-up and
investment strategies fueling growth in the sector. “As cell and gene therapies
transition from promise to practice, the industry must unite to overcome shared
challenges and seize new opportunities,” said Maurice Phelan, President of
Sartorius North America. “The Sartorius CGT Forum is designed to foster those
conversations, bringing the brightest minds together to accelerate innovation
and impact.”
Cédric Volanti, Head of ATS said, "The cell and gene
therapy field is at a pivotal moment, and technological advancements are
critical to making these life-changing therapies more affordable and
accessible.”
Full agenda, speaker lineup, and
registration details:
A profile of Sartorius Sartorius is a leading international
partner to life sciences research and the biopharmaceutical industry. With innovative laboratory instruments and
consumables, the Group’s Lab Products & Services Division focuses on laboratories performing
research and quality control at pharmaceutical and biopharmaceutical companies as well as academic research
institutes. The Bioprocess Solutions Division, with its broad product portfolio focusing on single-use
solutions, helps customers manufacture biotech medications, vaccines, and cell and gene therapies more
safely, rapidly, and sustainably. Based in Göttingen, Germany, the company has a strong global reach with
around 60 production and sales sites worldwide. Sartorius regularly expands its portfolio through the
acquisition of complementary technologies. In 2024, the company generated sales revenue of around
3.4 billion euros. More than 13,500 employees work for customers around the globe.
Visit our Newsroom or follow us on LinkedIn.
Head of Marketing BPS +491759558820
